Original article: Exploration of Unani concept of blood purifying drugs and likely models for its screening
Ansari Mushir1, Nasreen Jahan2*, Ghulamuddin Sofi3

Abstract
Introduction: In Unani system of medicine, blood is regarded as mixture of akhlat (humours) i.e. dam (Sanguine), balgham (phlegm), safra (yellow bile) and sawda (black bile). Normal blood consists of “akhlate latifa (plasma)” and “kaseefa (corpuscles)”. Normal blood is one in which all humours are in normal proportion in terms of quantity and quality and specific to each individual. It is normal in colour, free from bad odour and moderate in viscosity. Morbid blood develops due to impurities/disease in the blood which ultimately alter its quantity and quality. If we correlate these abnormalities with modern concept then all bleeding disorders and coagulopathy fall under “Riqqate dam” (low viscosity of blood); all the thromboembolic disorders; polycythemia, leukaemia and anaemia fall under “Ghilzate dam” (hyperviscosity of blood), while septicaemia, bacterial diseases can be correlated with “ufunat” (infections).

Methods: The classic and relevant books of Unani and conventional medicine were studied. The databases utilized for obtaining information, are scientific research publications from indexed journals available through Google Scholar, PubMed and Science Direct.

Results and Conclusion: Blood purifying drugs cause necessary changes and maintain the viscosity of the blood by their moderate heat; cold; dry and wet properties. These drugs are alterative and bring the quality and quantity of blood in equilibrium. Strengthen the defensive mechanism and eliminate toxins via sweat, urine, faeces etc. These drugs are digestive, tonic to stomach and liver and boost the immune system. In the line of the above conceptual framework few experimental models are being suggested i.e. effect of drugs on blood constituents, coagulation parameters, anaemia, leukaemia, polycythemia, thrombocytopenia and infections. This preliminary study may serve as a tool for the screening of blood purifier drugs in various blood disorders.

Keywords: Impure blood; Blood disorders; Unani concept; Experimental study; Blood purification

Introduction
In Unani system of medicine blood is regarded as a mixture of all humours i.e. sanguine, phlegm, yellow bile and black bile. Normal blood is one in which these four humours are in equal proportion with respect to their quantity and quality which is specific to each healthy individual. Thus any alteration in the quality and quantity of any of four humours in particular person makes the whole blood abnormal. Unani physicians state that morbid blood is caused by alteration in its temperament. The abnormal temperament means the quantity of matter with its kaifiat (hot, cold, moist, dry) exceeds from its normal proportion or any abnormality in humours. Ibn Rushd (1126-1198 A.D) mentioned that temperament of organ remains in its normal proportion when the blood which provides nutrition to it remains normal. This is only possible when the temperament of digestive organs is normal. Proper functioning of liver, stomach, kidney and spleen is necessary for the

1. Ansari Mushir, Department of Ilmul Advia, Dr MIJITU Medical Collage, Versova, Mumbai, 400061, Maharashtra
2. Nasreen Jahan, Department of Ilmul Advia, National Institute of Unani Medicine, Bengaluru, 560091, Karnataka
3. Ghulamuddin Sofi, Department of Ilmul Advia, National Institute of Unani Medicine, Bengaluru, 560091, Karnataka

Correspondence to: Nasreen Jahan, Department of Ilmul Advia, National Institute of Unani Medicine, Bengaluru, 560091, Karnataka, e-mail: nasreennium@gmail.com
production of normal blood. When the function of the liver is disturbed due to alteration in its temperament it ultimately affects the production of humours and also alters the quality and quantity of it.

Hematological disorders are quite frequent in all age group ranging deficiency disorder to relatively rare multiple myeloma. The magnitude of benign hematological disorders in India is shocking. Acquired hematological disorders occur due to iron and vitamin deficiency which indeed exceeds the congenital causes.

In the United States approximately 10,000 deaths were attributed to blood diseases in 2010. In which 1,900 were because of coagulation defects, 800 were due to purpura and 2,400 by other blood diseases. Treatment include corticosteroid therapy, blood transfusion, plasmapheresis, surgery, bone marrow cell transplant and life style changes.

None of these treatments alone offer an alternative for the definitive cure for blood diseases and the majority of treatments also have side effects.

There is no direct description of modern hematological diseases in ancient Unani classics; however, this does not mean that Unani medicine has not confronted with hematological diseases. Elaboration on signs and symptoms of traditional diseases elucidate their similarity to modern hematological diseases. Pathological changes that occur in various blood diseases are nearly parallel to morbid blood.

The valuable information about the concept of blood purifying drugs is scattered in the Unani literature, with different views pertaining to interpreting blood purifying drugs. In Unani system of medicine morbid blood is entertained only for skin diseases and blood purifying drugs show favorable outcomes in many of the skin ailments. A number of researches have also been carried out in this area but the above mentioned aspect is totally untouched by the Unani physicians and researchers. In this study all the relevant literature to blood purification and blood purifying drugs are compiled and explained in systematic way to minimize the differences in understanding of this core concept. This preliminary study not only explores the concept of blood purification but also sheds light on its potential in the management of blood anomalies.

**Methodology**

**Survey of literature for concept of blood purification**

An extensive search was carried out of Unani literature for concepts of blood, morbid blood and blood purifier drugs. All the Unani classical books and discussion with experts were conferred with for this study. Much emphasis has been given on its meaning, different views of Unani physician, mechanism of action, indications, therapeutic uses, present scenario and future research etc. Contemporary reference books, relevant articles, periodicals, peer reviewed indexed journals and other published work on PubMed, Science Direct, Google scholar etc. were surveyed to find out on going current theories and advancement in the field of hematology.

**Criteria evaluation**

Normal blood was defined with the help of Unani literature. Any derangement in the quantitative or qualitative determinants of blood was noted down and accordingly the criteria for blood purifying drugs were charted out.

**Survey of models for screening of blood purifying activity**

Animal models were searched in the various books of experimental pharmacology and relevant indexed journals in the light of the concept of morbid blood and its types, principles of treatment and mechanism of blood purification of Unani drugs. The models noted were explored in reference of the determinant searched from the Unani literature.

**Suitability of existing models**

After survey of literature a correlation of animal models and its suitability was ascertained in the light of Unani concept.

**Evaluation of suitable models**

On the basis of the criteria, several animal models were selected for the screening of blood purifying drugs which include effect of drugs on blood composition; anaemia; polycythaemia; thrombocytopenia; thrombosis; leukaemia; hyperlipidaemia and blood coagulation. These models are presently applied to screen drugs for various blood anomalies.

**Validation and reliability of the selected models**

From literature survey of morbid blood, mechanism of blood purification of Unani drugs was determined. The criteria for suitability of the animal models to screen the blood purifying drug activity were developed. The suitable tests were enumerated and their advantages were detailed.

**Results**

**Concept exploration: Characteristics of normal blood and morbid blood**

Regarding concept of blood, literature illustrates that blood is a mixture of all four humours i.e. sanguine, phlegm, yellow bile and black bile. Normal blood is one in which all humours are in normal proportion with respect to their quantity and quality and specific to each individual. It should be normal in colour, free from bad odour, moderate in viscosity and taste, free from putrefaction and acidity. Morbid blood
develops due to impurities or disease in the blood which ultimately alter its quantity and quality. Blood may become viscous, morbid, watery, black and sometime white. Whitish colour is due to addition of phlegm which is cold when compared to normal blood. Blackish colour is due to addition of black bile or excessive heat making it warmer than normal blood. Morbid blood may also affect its odour. It may be due to addition of any abnormal humour or due to infection in blood itself. The consistency of blood is also altered and it becomes viscous due to excessive phlegm and black bile or watery due to yellow bile.\(^4\)

**Concept of blood purifying drugs**

While going through the Unani literature it was noted that nearly all the blood purifying drugs are bitter in taste and hot and dry in second degree. These drugs are characterized by lenitive, detergent, laxative, deobstruent, alterative and irrigator properties. Because of these properties blood purifying drugs act as digestive, tonic to stomach and liver, diuretic, antiseptic, antipyretic and tonic to vital organs. Whereas elucidating its mechanism of action it was established that blood purifying drugs cause necessary changes in blood and remove its waste material so that the blood is purified from its impurities. Blood purifying drugs restore the normal viscosity of blood by their moderate heat, cold, dry and wet properties. These drugs bring the quality and quantity of humours or blood in equilibrium; produce and maintain normal blood by neutralizing the excessive heat of blood due to their alterative and moderate hot (lateef hararat) and dry properties. These drugs strengthen the defensive mechanism and prevent the body from toxins. They boost the immune system; normalize the blood composition and tone up the sluggish liver and kidney for its normal function. Blood purifying drugs eliminate toxicity of blood via sweat, urine, faeces etc. and internally cause some changes in blood; kill the morbid matters and purify the blood.\(^{14,15,16}\)

**Correlation with the present concept**

Blood becomes abnormal due to alteration in its composition. Alteration occurs both in quantity and quality.\(^{17,18}\) Quantity of blood may be increased or decreased while in quality viscosity of blood either increased or decreased or it may be infected due to toxins. If we correlate these abnormalities with modern concept of blood diseases then all bleeding disorder and coagulopathy fall under decreased viscosity of blood. Thromboembolic disorders, hyper coagulability, polycythaemia, leukaemia, anaemia, hyperlipidaemia and hyperglycemia fall under increased viscosity of blood, while septicemia, toxoaemia and other infectious diseases can be correlated with infections.

**Criteria for screening of blood purifying activity**

After extensive search of the literature it was noted that Blood purifier drugs act in several ways. (Table 1) Therefore, in the light of their mechanism some criteria (Table 2) have been selected for the screening of blood purifying activity of Unani drugs.

2 **Discussion**

According to Unani concepts, liver is the principal producer of many of the blood constituents. Spleen, kidney and gall bladder keeps blood clean. Proper functioning of these organs is necessary for production and maintenance of normal blood. When the function of the liver is disturbed it ultimately affects the production of blood and also alters its quality and quantity. A pathological change that occurs in morbid blood also depends upon surplus addition of other humours and changes the morphology of blood.\(^3\)

There is no exact description of modern hematological diseases in ancient Unani classics; however, this does not mean that Unani medicine has not been confronted with hematological diseases. There is a description for blood diseases in Moalijate Buqratia,\(^{14}\) Firdausul Hikmat(775-890 AD)\(^{16}\) and Tibbe Akbar(1721 AD).\(^{17}\) Pathological changes that occur in hematological diseases are highly correlated to morbid blood and signs and symptoms of blood diseases are almost similar to signs and symptoms of morbid blood. Spleenomegaly is the crucial diagnostic sign in all diseases of blood, interestingly Unani physicians have mentioned that in case of spleen enlargement, body and liver becomes weak therefore liver is unable to produce blood and simultaneously spleen absorb more amount of blood which leads to further shortage of blood. Fatigue, weakness, tiredness, fever these entire symptoms were described by ancient physicians under splenic diseases\(^{15}\) and same symptoms are mentioned in conventional medicine under caption of various hematological disorders.

Alteration in the blood whether in quantity or quality is one of the primary causes of morbid blood. Therefore, a test was included for effect of drugs on normal parameters of blood which aimed to determine whether the blood purifying drugs alter the normal parameters of blood and also to determine the underlying mechanism. For this purpose two groups of 12 rats (control and test) are tested to determine pre-treatment values. After the treatment for 21 days in test group blood samples are collected for the effects on BT, CT, RBC, Hb%, WBC, Platelet count, ESR, Osmotic fragility, Fibrinogen level, Glucose,
Table 1: Mechanism of action and therapeutic uses of Musaffie dam drugs

| Actions | Mode/mechanism of action | Therapeutic uses |
|---------|--------------------------|------------------|
| Muhallil (Resolvent) | Resolve thick and viscous humours | Inflammation of liver and spleen |
| Mulattif (Lenitive) | Liquefy thick and viscous humour | Hyperviscosity of blood due to phlegmatic humour in hyperlipidaemia and hyperglycemia |
| Mujaffif (Siccative) | Resolve viscous humours lying deep in the cavity and dry the exudates | Inflammation and ulcers |
| Mu’arriq (Diaphoretic) | Through perspiration remove waste material | Skin diseases and fever |
| Mufattih (Deobstruent) | Agitate the humoral matter lying deep in the cavity or orifice and open the passage to remove the obstruction | Obstruction in the liver and spleen, thrombosis |
| Mudirr-i-Bawl (Diuretic) | Increase viscosity of blood and remove waste material | Infection, fever, skin diseases |
| Dafi’-i-Ta’affun (Antiseptic) | Clear sepsis | Infections |
| Mushil (Purgative) | Expulsion of morbid humours by intestine | Diseases caused by altered temperament with involvement of morbid matter |
| Dafi’-i-Humma (Antipyretic) | Reduce body temperature during fever | Fever due to infection |
| Muqawwii-i-Mi’dwa jigar (Tonic to stomach & liver) | Strengthen and tone up the stomach and liver and improve its function | Stomach and liver diseases |
| Muqawwii-i-Tihal (Tonic to spleen) | Strengthen the spleen and improve its function | Diseases of spleen |
| Mushthai (Appetizer) | Promote the desire for food | Loss of appetite due to stomach and liver diseases |
| Hādim (Digestive) | Improves digestion | Indigestion and weakness of stomach |

Protein and Lipid concentration. In a study effects of Safi (Unani formulation of blood purifier drugs) and an allopathic hematinic Sangobion were observed on haematological and biochemical parameters in human volunteers. The increase in haemoglobin and erythrocytes was more prominent by Safi.¹⁸

Faqruddam (Anaemia) is denoted by various terms like ‘Fasade Dam’, ‘Khūn ki tabahi’ and ‘Sooul Qiniya’ in Unani literature.¹³ Improper function of liver affects the quality and quantity of blood. Blood purifying drugs maintain the specific composition of blood by their immunomodulator and hematopoetic properties.¹⁴ India root has beneficial role in su ul qinya¹⁴ and prevent from premature destruction of blood. Indian gooseberry,¹⁴-¹⁵ Chiretta and a combination of Indian gooseberry and neem²⁰ showed hematinic efficacy in hemolytic anaemia. Sarsaparilla (Smilax aristolochiaefolia) was also found effective in benzene induced aplastic anaemia.⁹ The blood purifying drugs contain saponins,²¹ phenols,²² phenolic glycosides, alkaloids²³ vitamins²⁴ and minerals.²⁵ Triterpenic saponins stimulate the proliferation of lymphocytes for the production of interferon, hematopoetic growth factors and cytokines.²⁶ Alkaloids enhance the restoration of haematopoiesis.²⁷ The drugs which contain alkaloid, flavonoid, saponins have anti oxidant property so indirectly can be used in anaemia.²⁸ In the light above properties, two experimental models have been proposed viz. Phenylhydrazine.
induced hemolytic anaemia and benzene induced aplastic anaemia. Hemolytic anaemia is induced in Wistar rats by PHZ at 40 mg/kg orally for two days. Thereafter, the animals are treated with the test drug for 15 days. While aplastic anaemia is induced in male Swiss mice by 2 ml (1940 mg/kg) benzene subcutaneously. Three doses of benzene are administered weekly on alternate days until 10 doses are completed. After that, animal is treated with test drug for 15 days. The effect of test drug in both the models is evaluated by the estimation of RBC, WBC, Hb, hematocrit and LFT.

Hemolytic anaemia is associated with intoxication with chemicals and drugs. PHZ is a strong oxidant agent. It shortens life span of RBC resulting in severe hemolytic anaemia. Flavonoids are found in babchi, chiretta, mundi, and sandalwood. So blood purifying drugs may prove the haematinic potentials due to presence of these phytoconstituents.

Thrombocytopenia may result from intake of drug, chemicals, chronic liver disease and dengue hemorrhagic fever. This condition can be correlated with “riqqate dam” (low viscosity of blood). As riqqate dam is one of the causes of jiryanuddam (haemorrhage) and qatma (hemorrhage beneath the skin). Low platelet count is most likely caused by ethanol causing portal hypertension and hypersplenism which resulted in thrombocytopenia. Liver damaged by ethanol can decrease production of thrombopoetin which decreases platelet production. Thrombocytopenia is induced in rats by ethanol 3 g/ kg ip for seven days. From 8th day the animals are treated with the test drug for further 14 days. The platelet count, bleeding and clotting time and histopathological analysis of the liver and spleen is done. The increase in bleeding time predisposes to prolonged hemorrhage and consequently excessive blood loss. This directly correlates with the decrease in the number of platelets in circulation. Clotting time measures the degree of activation of the coagulation pathways. Blood purifying drugs are tonic to liver and spleen, restore the functions of these organs and normalize the blood composition. Jujube is used in riqqate dam (blood liquefaction). It normalizes excessive heat of blood and makes the blood less

| Model for the diseases          | Suitability                                                                 | Limitation                                      |
|---------------------------------|-----------------------------------------------------------------------------|------------------------------------------------|
| Anaemia                         | Nutritional anaemia, hemolytic anaemia, anaemia due to chronic inflammation | Anaemia caused by congenital defect like thalasemia, sickle cell anaemia |
| Thrombocytopenia /purpura       | Acquired caused by exposure to chemicals, bacterial and viral infections    | Congenital                                      |
| Polycythaemia                   | Primary polycythaemia                                                      | Secondary polycythaemia                        |
| Leukaemia                       | Chronic leukaemia                                                           | Acute Leukaemia                                |
| Thrombosis                      | Atherosclerosis deep vein thrombosis ecchymosis                             | Stroke                                         |
| Infection and fever             | Mild and chronic infection                                                  | Acute infection                                |
| Hyperlipidaemia and Blood Coagulation | Atherosclerosis Hypertension                              | Stroke, embolism, IHD                          |
| Hepatic and Stomach function    | Jaundice, hepatitis, weakness of liver and stomach                          | Gastric ulcer, carcinoma of stomach and liver  |

Table 2: Suitability and limitation of selected animal models for Musaffie dam drugs
A deficiency in factors VII, IX, XII, XIII and von Willebrand's factor. Coagulation prolonged activated partial thromboplastin time (aPTT) are used to determine the coagulation basis above properties an in vitro model for the preliminary screening of blood purifying drugs has been selected. Polycythaemia is induced in rats by inhalation of cobalt chloride (30mg/m³), 6hrs/day and 5 days a week for 13 weeks. Increased blood viscosity in polycythaemia may be due to excessive black bile.

Blood purifying drugs may be effective by purgation of black bile and normalize the function of spleen. Interestingly these drugs contain saponins can replace the use of aspirin in polycythaemia. Abyazudnam (Leukaemia) is characterized by abnormal proliferation, differentiations and overproduction of WBC and their precursors at which viscosity of blood is increased. Clinical features of leukaemia include weakness, lethargy, weight loss, fever, night sweats, and enlarged spleen and lymph nodes. This can be correlated with sign and symptom of “azme tihal”. Hippocrates quotes that when spleen enlarges body becomes week, which is noticeable in leukaemia. Leukaemia is induced in rats by 0.2 mL of a 1:10 diluted benzene solution every 2 days for 3 consecutive weeks. Blood purifying drugs by their alterative property may be effective in normalizing the quantity of these cells. Further these drugs have anti cancer, anti inflammatory activities. These drugs also rich in flavonoids and alkaloids. Alkaloids and flavonoids block the tyrosine phosphorylation, induce caspase-3 activity and release the cytochrome C to activate the caspase-9, and induce the expression of CD95 to induce apoptosis. Immune function is disturbed in hematological diseases. Indian gooseberry, china root etc. strengthen the defensive mechanism and prevent the body from toxins. Tannin, saponin, sterols and triterpene glycosides are found in drugs. It has been established that saponins have adjuvant effects on humoral cell mediated immunity. Tannins, sterols and triterpene glycosides are immunostimulant.

The coagulation system has been intended as a possible mechanism of thrombogenesis and atherosclerosis in patients with hyperlipidaemia. Hyperlipidaemia is a risk factor for ischemic heart disease, suggesting that hypercoagulability may perform a role in patients with hyperlipidaemia. Hence alterations in lipid levels influence thrombosis by modifying the activity of coagulation proteins, platelets and fibrinolytic
Therefore, the model has been designed to evaluate the effects of blood purifying drugs on lipid profile and blood coagulation in hyperlipidaemia induced in rabbits by high cholesterol diet for 45 days. Thereafter animals are administered with the test drug orally for 30 days. Highly significant increase in thrombin time (TT) indicates deficiency of fibrinogen or inhibition of thrombin. Significant decrease in cholesterol, triglyceride and LDL-C and at the same time increase in TT and fibrinogen time, indicating the probable decrease in the risk of atherosclerosis. Hence there are links between lipids and the haemostatic mechanisms which affect atherosclerotic, vasomotor and thrombotic components of ischemic heart disease. So these models can be utilized for the screening of blood purifying drugs.

On the basis of above discussion it can be implicit that concept of morbid blood is a very wide in Unani system of medicine. The different properties of the blood purifying drugs such as alternative, anti-inflammatory, hematopoietic, tonic and demulcent comes from its bitter taste and hot and dry temperament. Demonstration of various effects such as tonic to stomach and liver, digestive, appetizer, diuretic, anti septic, antipyretic along with its research reports may give rise to total effects in amelioration of hematological disorders. Since blood purifying drugs possess a wide range of pharmacological effect, therefore it can be said that it may prove its effectiveness by evolving a holistic paradigm and involving its numerous actions. Saponins, flavonoids, alkaloids, vitamins, minerals, tannins, glycosides, amino acids, steroids, triterpenoids, etc. present in the drug further corroborates the proposition that the blood purifying drugs may produce effect through diverse mechanism complementing each other.

**Conclusion**

It can be concluded therefore, that the effect of blood purification may be related to all the above reported actions and chemical constituents of the drugs which may act to ameliorate the morbid blood. So this study may serve as a tool for screening the blood purifying drug which is one of the broadest terms for the effect of drugs in disorders of blood.

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflict of interest:** None

**Authors’ Contribution:**

Data gathering and idea owner of this study: Ansari Mushir, Nasreen Jahan

Study design: Ansari Mushir, Nasreen Jahan, Ghulamuddin Sofi

Data gathering: *Ansari Mushir, Nasreen Jahan*

Writing and submitting manuscript: *Ansari Mushir, Nasreen Jahan*

Editing and approval of final draft: *Ansari Mushir, Nasreen Jahan, Ghulamuddin Sofi*

**Conflict of interest:** None
References:
1. AH Israili. Humoral theory of Unani Tibb. Indian Journal of History of Science,1981;16(1):95-99
2. Lone AH., Ahmad T, Anwar M, Sofi G, Imam H, Habib S. Perception of Health promotion in Unani herbal medicine. Journal of Herbal Medicine 2012;2:1-5
3. Kaberuddin M. Kulliyat-e-Qanun. Lahore: Sheikh Muhb Basheer and Sons; 1930: 45,210.
4. Jurjani AH. Zakhira Khwazam Shahi (Urdu translation by Khan HH). Vol. b.II,III,VII. New Delhi: Idara Kitaush-Shifa; 2010: 8,14,23,24,25,32,88,195, 196.
5. Rushd AW. Kitabul Kulliyat (Urdu translation by CCRUM). 2nd ed. New Delhi: CCRUM; 1987: 45, 81, 90,106,109,114,442.
6. Demaeyer E, Adiels TM. The prevalence of anaemia in the world. World Health Statistics Quarterly. 1985; 38(3): 302-316.
7. Dutta TK. Benign hematological disorders in India: The status. International Journal of Advanced Medical and Health Research. 2014; 1:35-6.
8. National institute of health. Disease statistics. 2012 .http://www.nhlbi.nih.gov.
9. Velasco RL., Torres AM, Aguilar RT, Saenz JLF, Padilla MF, Avila EV et al., Hematopoietic activity of Aristolochiaefolia (Zarzaparrilla) in mice with aplastic anemia. Proc. West. Pharmacol Soc. 2009; 52: 83-87.
10. Akhtar S, Khan BD, Aleem S. Evaluation of Itifil-e-Shahatra and Roghan-e-Babchi in Case of Daa-us-Sadaf. Hippocratic Journal of Unani Medicine 2011; 6: 11-22.
11. Hasan TSS, Aleem S, Tabassum L. Clinical evaluation of efficacy of Majoon Ushba and marham gulabi in qooba. Indian journal of traditional knowledge. 2011; 10: 02-705.
12. Mashti IQ. Kitabul Umda Fil Jarahat (Urdu translation by CCRUM). Vol. I, II. New Delhi: CCRUM; 1986: 118,19,20.
13. Razi AMBZ. Kitabul Mansuri (Urdu translation by CCRUM). New Delhi: CCRUM; 1991: 19, 51-53 201.
14. Tabri AM. Moalijat-e-Bugratiya (Urdu translation by CCRUM). Vol II. New Delhi: CCRUM; 1997: 188,216.
15. Khan MA. Akseer-e-Aazam (urdu). New Delhi: Aejaz Publishing House; 2010: 519,866.
16. Tabari A R. Firdausul Hikmat (Urdu translation by Sanbhali S). New Delhi: Idara Kitab-ush-Shifa; 2010: 30, 31,52,87,88,124.
17. Arzani A. Tibb-e-Akbar (Urdu translation by Husain). New Delhi: Idara Kitab-ush-Shifa; (Ym): 458,467.
18. Baig SG, Ahmed SP, Khan RA, Ali SS. Comparative studies of Safi and ferrous gluconate on human volunteers. Pakistan Journal of Pharmacology. 2002 July; 19(2): 21-31.
19. Turaskar A, More S, Sheikh R, Gadhpayle J, Bhongade SL, Shend V. Antinaemic potential of Swertia chirata on phenylhydrazine induced reticulocytosis in rats. AJPCT. 2013; 1(1): 037-041.
20. Vamsee VA, Jyothi Y, Pokhrel R, Ghosh R, Patidharand R, Yadav V. Comparative anti anemic activity of Azadirachta indica leaves and its combination with Emblica officinalis in phenyl hydrazine induced anaemia using rats. Journal of Chemical and Pharmaceutical Research. 2015; 7(8): 1019-22.
21. Jayprakasam P, Ravit K, Kuriakose A, Asha JB. Quantitative determination of diosgenini in polyherbal formulation and various extracts of Smilax china Linn. using standard marker by validated analytical technique. UJP. 2013; 02 (04): 83-90.
22. Bano Q, Wahid M, Irfan M, Chaurasiya V, Iqbal I, Nawaz S, Saeed K, Shahzad Q. Ethno-pharmacological and phytochemical constituents review of Echinops echinatus roxb. J App Pharm. 2015 January; 7(1): 69-74.
23. Brahmacari G, Mondal S, Gangopadhyay A, Gorai D, Mukhopadhyay B, Saha S, Brahmacari AK. Swertia (Gentianaceae): Chemical and Pharmacological Aspects. Chemistry & Biodiversity. 2004; 1: 1627-50.
24. Jain SK, Khurdiya DS. Vitamin C enrichment of fruit juice based ready-to-serve beverages through blending of Indian gooseberry (Emblica officinalis Gaertn.) juice. Plants foods for human nutrition journal. 2004; 59(2): 63-6.
25. Li JW, Fan LP, Ding SD, Ding XL. Nutritional composition of five cultivars of Chinese jujube. Food Chemistry. 2007; 103: 454-60.
26. Van Zant G, de Haan G, Rich IN. Alternatives to stem cell renewal from a developmental viewpoint. Experimental Hematology; 1997; 25: 187-192
27. Boyko VN, Belskiy SN. The influence of the novel drug Ukrain on hemo- and im-munopoeis in the time of its maximum radioprotective effect. Drugs Exp Clin Res. 1998; 24(5-6): 335-337.
28. Celik G, Yontem M, Bilge M, Cilo M, Unalld M. The relationship between the antioxidant system and anaemia in haemodialysis patients. J Int Med Res. 2011; 39(5): 1954-60.
29. Itano HA, Hirota K, Hosokawa K. Mechanism of induction of haemolytic anaemia by phenylhydrazine. Nature.1975; 256, 665–667.
30. Cui Y, Taniguchi S, Kuroda T, Hatano T. Constituents of Psoralea corylifolia fruits and their effects on Methicillin-resistant Staphylococcus aureus. Molecules. 2015; 20: 12500-11.
31. Galani VJ, Patel BJ, Rana DJ. Sphaeranthus indicus Linn.: A phytopharmaceutical review. Int J Ayurveda Res. 2010 Oct-Dec; 1(4): 247-53.
32. Narayan S, Devi RS, and Devi CSS. Role of *Pterocarpus santalines* against mitochondrial dysfunction and membrane lipid changes induced by ulcerogens in rat gastric mucosa. *Chem Biol Interact.* 2007; 170: 67-75.
33. Shad AA, Ahmad S, Riazullah, Salam NA, Fouad H, Rehman NU, Hussain H, Saeed W. Phytochemical and biological activities of four wild medicinal plants. Hindawi Publishing Corporation. *Scientific World Journal.* 2014:1-7.
34. Ogbe RJ, Adoga GI, Abu AH. Antianemic potentials of some plant extracts on phenyl hydrazine-induced anemia in rabbits. *Journal of Medicinal plants Research.* 2010; 4(8): 680-684.
35. The Wealth of India. First supplement series (Raw Materials), Second print, Vol-5: R-Z, National Institute of Science Communication & Information Resources, CSIR, 2004: 421.
36. Singh E, Sharma S, Pareek A, Dwivedi J, Yadav S, Sharma S. Phytochemistry, traditional uses and cancer chemopreventive activity of Amla (*Phyllanthus emblica*). The Sustainer. *Journal of Applied Pharmaceutical Science.* 2011; 02 (01): 176-83.
37. Facino RM, Carini M, Franzoi L, Pirola O, Bosisio E. The Wealth of India. First supplement series (Raw Materials), Second print, Vol-5: R-Z, National Institute of Science Communication & Information Resources, CSIR, 2004: 302.
38. Suhashini R, Sindhu S, Sagadevan E. In vitro evaluation of antidiabetic potential and phytochemical profile of *Psoralea corylifolia* seeds. *IJPPR.* 2014 June-August; 6(2): 414-419.
39. Li YR, Cao W, Guo J, Miao S, Ding GR, Li KC, Wang J, Guo GZ. Comparative investigations on the protective effects of rhodioside, ciwujianoside-B and astragaloside IV on radiation injuries of the haematopoi-etic system in mice. *Phytother Res.* 2011. 25(5): 644-53.
40. Izak M Bussel JB. Management of thrombocytopenia. *F1000Prime Reports.* 2014; 6: 45.
41. Qarshi H. *Jamiul Hikmat.* New Delhi: Idara Kitab-ush-Shifa; 2011: 573, 579, 611, 618.
42. Afdhal N, McHutchison J, Brown J, Jacobson I, Manns M, Poordad F et al., Thrombocytopenia associated with chronic liver disease. *Journal of Hepatology.* 2008; 48: 1000-7.
43. Salem RO, Laposata M. Effects of alcohol on hemostasis. *American Journal of Clinical Pathology.* 2005; 123: 96-105.
44. Littleton J, Fenn CG, Umney ND, Yazdanbakhsh M. Effect of Ethanol administration on platelet function in the rat. Alcoholism: *Clinical and Experimental Research.* 2008; 6(4): 512-519.
45. Apostol JG, Gan JVA, Raynes RJB, Sabado AAS, Carigma AQ, Santiago LA and Israel MC. Platelet-increasing effects of *Euphorbia hirta* Linn. (*Euphorbiaceae*) in ethanol-induced thrombocytopenic rat models. *Internl J Pharm Frontier Res.* 2012; 2(2): 1-11. http://www.ijpjfr.com/Documents/2/1
46. Patil S, Shetty S, Bhide R, Narayanan S. Evaluation of platelet augmentation activity of *Carica papaya* leaf aqueous extract in rats. *Journal of Pharmacognosy and Phytochemistry.* 2013; 1 (5): 57-60.
47. Basma AA, Zakaria Z, Latha LY, Sasidharan S. Antioxidant activity and phytochemical screening of the methanol extracts of *Euphorbia hirta* L. *Asian Pacific Journal of Tropical.* 2011; 4: 386-390.
48. Majoosi AA. Kamil ul Sanaa, (Urdu translation by Kantoori GH). Vol-I, New Delhi: Idara Kitabusi Shifa; 2010: 302.
49. Lu WQ, Qiu Y, Tao X, Sun LN, Chen WS. Antiplatelet and antithrombotic activities of timosaponin B-II, an extract of *Anemarrhena asphodeloides*. *Clin Exp Physiology.* 2011 Jul; 38(7): 430-4.
50. Shahriar M, Islam MS, Parvin S, Hoque S. Thrombolytic activity and antimicrobial properties of *Ficus hispida*. *J. Sci. Res.* 2013; 5(2): 393-397.
51. Prasad S, Kashyap RS, Deopujari JY, Purohit JH, Taori GM, Daginawala HF. Development of an in vitro model to study clot lysis activity of thrombolytic drugs. *Thrombosis journal.* 2006; 4(14): 1-4.
52. Orfao SC, Jank G, Mottaghy K, Walcher S, Zerz E. Qualitative properties and stabilizability of a model for blood thrombin formation. *J Math Analysis App.* 2008; 346: 218-26.
53. Yaun S, Ferrell C, Chandler WL. Comparing the prothrombin time INR versus the aPTT to evaluate the coagulopathy of acute trauma. *Thrombosis Research.* 2007; 120: 29-37.
54. Laffan MA, Bradshaw AE. Investigation of haemostasis. In: Dacie JV, Lewis SM (Eds.). Practical Haematology. Eighth ed. Churchill Livingstone: Edinburgh; 1995:297-315.
55. Provan D. ABC of clinical haematology. 2nd ed. London: BMJ Books; 2003: 14.
56. National Toxicology Program. NTP toxicology and carcinogenesis studies of cobalt sulfate heptahydrate (cas no. 10026-24-1) in F344/n rats and b6c3f1 mice (inhalation studies). *Natl Toxicol Program Tech Rep Ser.* 1998 Aug; 471: 1-268.
57. Pawinwongchai J, Chanprasert S. Antileukemic activity of *Houttuynia cordata* Thumb. extracts in Jurkat and U937 human leukemic cells. *J. Chem. Pharm. Res.* 2011; 3(4): 204-212.
58. Oluwemi AE, Terry AO, Kola OJ. Anti-leukemic and immunomodulatory effects of fungal metabolites of...
Exploration of Unani concept of blood purifying drugs and likely models for its screening

Pleurotus pulmonarius and Pleurotus ostreatus on benzene-induced leukemia in Wister rats. *Korean J Hematol.* 2012 Mar; 47(1): 67-73.

59. Muralidhar A, Somasekhar A, Sumanjali A, Kumar BP, Prasanna BL, Vali TCS et al., Anticancer activity of *Tephrosia purpurea* root extracts against Ehrlich Ascites Carcinoma (EAC) cells in Swiss albino mice. *Der Pharmacia Sinica.* 2014; 5(2): 81-87.

60. SJ Wasu, BP Muley. Antioxidant activity of *Fumaria officinalis* Linn. and its study on ethanol induced – immunosuppression. *Research J. Pharm. and Tech.* 2009 April-June; 2(2): 405-408.

61. Varma RR and Vijayamma N. Pharmacological studies on Raktchandana. *J Res Ayurved Sidd.* 1991; 12: 190-199.

62. Banerjee S, Sur TK, Mandal S, Das PC, Sikdar S. Assessment of the anti-inflammatory effects of *Swertia chirata* in acute and chronic experimental models in male albino rats. *Indian Journal of Pharmacology.* 2000; 32: 21-24.

63. Ghosh R, Sharatchandra K, Rita S, Thokchom IS. Hypoglycemic activity of *Ficus hispida* (bark) in normal and diabetic albino rats. *Indian J Pharmacol.* 2004 August; 36 (4): 222-225.

64. Muthian G, BrightJJ. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. *Journal of Clinical Immunology.* 2004, 24(5), 542-552.

65. Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. *European Journal of Cancer.* 1999; 35(10): 1517-25.

66. Lugli E, Ferraresi R, Roat E, Troiano L, Pinti M, Nasi M, et al., Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells. *Leukemia Research.* 2009; 33: 140-150.

67. Iqbal RZ, Hua HUS, Wen XC, Abdullah AG. Adjuvant effects of saponins on animal immune responses. *Journal of Zhejiang University-Science B.* 2007; 8(3): 153-161.

68. Heroor S, Beknal A, Mahurkar N. Immunomodulatory activity of methanolic extracts of *Pongamia glabra* Vent. seeds and bark in cyclophosphamide induced mice. *RGUHS J Pharm Sci.* 2012; 2(1): 74–77.

69. Burlando B, Verotta L, Cornara L, Bottini-Massa E. Herbal Principles in Cosmetics: Properties and Mechanisms of Action. *Boca Raton.* Florida: CRC Press; 2010: 460.

70. Bedir E, Pugh N, Calis I, Pasco DS, Khan IA. Immunostimulatory effects of cycloartane-type triterpene glycosides from astragalus species. *Biological and Pharmaceutical Bulletin.* 2000; 23(7): 834–837. [PubMed].

71. soki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, et al., Platelet-Dependent Thrombin Generation in Patients with Hyperlipidemia. *Journal of American College of Cardiology.* 1997 July; 30(1): 91–6.

72. Eitzman DT, Westrick RJ, Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. *Blood.* 2000; 95: 577-580.

73. Lane DA, Philippou H, Huntington JA. Directing Thrombin. *Blood.* 2005; 06: 2605-12.

74. Tousoulis D, Davies G, Ambrose J, Tentolouris C, Stefanadis C, Toutouzas P. Effects of lipids on thrombotic mechanisms in atherosclerosis. *International Journal of Cardiology.* 2002; 86(2-3): 239-247.